Author

Isabelle Genvresse

Observed names: Genvresse, Isabelle, I Genvresse, I. Genvresse

Observed institutions: Humboldt-Universität zu Berlin, Hôpital Avicenne, Hôpital Bichat-Claude-Bernard, Stiftung Charité, Bayer (Germany), Freie Universität Berlin, Charité – Universitätsmedizin Berlin

ORCID: 0009-0001-2968-6945

Observed ORCID: 0009-0001-2968-6945

OpenAlex ID: A5067111908

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

2016 · A. Patnaik, L.J. Appleman, et al. · Annals of Oncology · 239

PDF

Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation

2002 · G Massenkeil, S Rackwitz, et al. · Bone Marrow Transplantation · 96

Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved

2003 · G Massenkeil, M Nagy, et al. · Bone Marrow Transplantation · 79

Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas

2000 · E Späth-Schwalbe, I Genvresse, et al. · Anti-Cancer Drugs · 70

Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

2021 · Antje Wick, Oliver Bähr, et al. · Clinical Cancer Research · 69

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

2020 · Michael Heuser, Neil Palmisiano, et al. · Leukemia · 58

PDF

Prevalence and clinical significance of anticardiolipin and anti‐β2‐glycoprotein‐I antibodies in patients with non‐Hodgkin's lymphoma

2002 · I. Genvresse, D. Lüftner, et al. · European Journal Of Haematology · 57

First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy

2022 · Jennifer R. Diamond, Valentina Boni, et al. · Clinical Cancer Research · 55

PDF

Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

2020 · Ramesh K. Ramanathan, Daniel D. Von Hoff, et al. · Targeted Oncology · 52

PDF

On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors

2019 · Franck Morschhauser, Jean-Pascal Machiels, et al. · Molecular Cancer Therapeutics · 41

PDF

Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer

2018 · R D Kim, S R Alberts, et al. · British Journal of Cancer · 41

PDF

Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study

2001 · Isabelle Genvresse, Catalina Lange, et al. · Anti-Cancer Drugs · 23

Cefixime

1993 · Isabelle Genvresse, Claude Carbon · International Journal of Antimicrobial Agents · 20

Arterial thrombosis associated with anticardiolipin and anti‐β2‐glycoprotein‐Iantibodies in patients with non‐Hodgkin's lymphoma: a report of two cases

2000 · I. Genvresse, F. Buttgereit, et al. · European Journal Of Haematology · 18

Primary hepatic or splenic diffuse large B-cell lymphoma and hepatitis C virus infection: a non-fortuitous association?

2000 · I. Genvresse, E. Späth-Schwalbe, et al. · Annals of Hematology · 16

Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL).

2021 · Victor Moreno, Raul Cordoba, et al. · Journal of Clinical Oncology · 15

Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [14C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers

2017 · Michael Gerisch, Thomas Schwarz, et al. · Cancer Chemotherapy and Pharmacology · 15

PDF

Primäres zerebrales hochmalignes B-Zell-Lymphom vom Burkitt-Typ

1999 · E. Späth-Schwalbe, I. Genvresse, et al. · DMW - Deutsche Medizinische Wochenschrift · 14

First-in-Human Dose-Escalation Study of the First-in-Class PDE3A–SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A

2024 · Kyriakos P. Papadopoulos, Meredith McKean, et al. · Clinical Cancer Research · 12

PDF

Phase I Study of Intravenous PI3K Inhibitor Bay 80–6946: Preliminary Activity in Patients with Relapsed Non-Hodgkin Lymphoma (NHL) Treated in an MTD Expansion Cohort

2012 · Amita Patnaik, Ramesh K Ramanathan, et al. · Blood · 11

Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkinʼs lymphoma—a phase II study

2002 · Ernst Späth-Schwalbe, Catalina Lange, et al. · Anti-Cancer Drugs · 11

Subacute encephalopathy after combination chemotherapy including moderate-dose methotrexate in a patient with gastric cancer

1999 · I Genvresse, A Dietzmann, et al. · Anti-Cancer Drugs · 9

Autologous peripheral blood stem cell transplantation of stem cells harvested in imatinib-induced complete cytogenetic remission: an example of in vivo purging in CML

2003 · P le Coutre, K A Kreuzer, et al. · Leukemia · 7

Phase 1 dose escalation study of copanlisib (BAY 80-6946) in combination with gemcitabine or gemcitabine-cisplatin in advanced cancer patients.

2014 · Richard D. Kim, Steven R. Alberts, et al. · Journal of Clinical Oncology · 6

Delayed response to granulocyte colony‐stimulating factor (G–CSF) in a case of severe neutropenia associated with large granular lymphocyte (LGL) leukemia

1998 · I. Genvresse, E. Späth‐Schwalbe, et al. · European Journal Of Haematology · 6

Works count: 121

Citation count: 1,076

H-index: 15

I10-index: 21